share_log

Tonix Pharmaceuticals Secures $34M DOD Contract, Collaborates With X-Chem on Antiviral Research to Boost Development of Oral Antivirals Using AI and ML

Tonix Pharmaceuticals Secures $34M DOD Contract, Collaborates With X-Chem on Antiviral Research to Boost Development of Oral Antivirals Using AI and ML

tonix pharmaceuticals獲得3400萬美元的國防部合同,與X-Chem合作進行抗病毒研究,以推動利用人工智能和機器學習開發口服抗病毒藥物。
Benzinga ·  10/08 07:12

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that it has entered into an AI and ML research collaboration with X-Chem, Inc. (X-Chem), a leader in small molecule drug discovery, to accelerate development of Tonix's oral broad-spectrum antivirals.

tonix pharmaceuticals控股公司(NASDAQ:TNXP)(Tonix或公司)是一傢俱有上市產品和開發候選藥物管道的全面集成生物製藥公司,今日宣佈已與小分子藥物研發領導者X-Chem公司(X-Chem)達成人工智能和機器學習研究合作協議,以加速開發tonix的口服廣譜抗病毒藥物。

Tonix's TNX-4200 antiviral program focuses on the development of oral CD45 phosphatase inhibitors, with broad-spectrum activity against a range of viral families. As previously disclosed, Tonix entered into a contract with the U.S. Department of Defense's Defense Threat Reduction Agency (DTRA) for up to $34 million to advance the development of Tonix's TNX-4200 broad-spectrum oral antiviral program for medical countermeasures, including an Investigational New Drug (IND) submission and a first-in-human Phase 1 clinical study.

tonix的TNX-4200抗病毒項目專注於開發口服CD45磷酸酶抑制劑,對多種病毒家族具有廣譜活性。正如之前披露的,tonix與美國國防部的國防威脅削減局(DTRA)簽訂了一份高達3400萬美元的合同,用於推進tonix的TNX-4200口服廣譜抗病毒項目的開發,包括提交新藥申請(IND)和第一階段人體臨床研究。

"We are excited to enter into this research collaboration with X-Chem, which we believe will expand our capabilities, and deepen our understanding of host-targeted small molecule therapeutics for a variety of targets," said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals. "With the support of X-Chem's drug discovery AI/ML technology, we expect to optimize the physicochemical properties, pharmacokinetics, and safety attributes of our drug candidates."

「我們很高興與X-Chem展開這項研究合作,我們相信這將擴大我們的能力,並加深對小分子藥物靶向宿主療法在各種目標上的理解,」tonix pharmaceuticals首席執行官Seth Lederman博士表示。 「在X-Chem的藥物發現人工智能/機器學習技術的支持下,我們預計能優化我們的藥物候選物的物理化學性質,藥代動力學和安全特性。」

"We are excited to partner with Tonix in their pursuit of such important programs in human health, at the intersection of laboratory and in silico technology. This collaboration highlights how integrative work continues to leverage the creation of target-specific high-quality data to drive AI drug discovery," said Erin Davis, Ph.D., Chief Technology Officer of X-Chem."

「我們很高興能與tonix合作,共同致力於人類健康領域如此重要的項目,這涉及實驗室和仿真技術的交叉點。這種合作突顯了整合工作如何繼續利用創造目標特異性高質量數據來推動人工智能藥物發現,」X-Chem首席技術官Erin Davis博士表示。

The DTRA contract awarded to Tonix is expected to help fund and accelerate the development of the Company's lead oral host-directed TNX-4200 broad-spectrum antiviral program. The TNX-4200 program aims to reduce viral load and to allow the adaptive immune system to alert the other arms of the immune system to mount a protective response. Tonix plans to leverage previous research on phosphatase inhibitors to optimize lead compounds for therapeutic intervention of biothreat agents.

DTRA授予tonix的合同預計將有助於資助並加速公司主導口服宿主導向TNX-4200廣譜抗病毒項目的開發。TNX-4200項目旨在降低病毒載量,並使適應性免疫系統警覺其他免疫系統部分以發動保護性響應。tonix計劃利用先前的磷酸酶抑制劑研究,以優化首要化合物,用於治療生物威脅制劑干預。

For the oral broad-spectrum antiviral programs, including TNX-4200, Tonix is utilizing its state-of-the-art research laboratory capabilities, including a Biosafety Level 3 (BSL-3) lab and an Animal Biosafety Level 3 (ABSL-3) facility at its research and development center (RDC) located in Frederick, Md., as well as experienced personnel in-house. The RDC is located in Maryland's 'I-270 biotech corridor' and is close to the center of the U.S. biodefense research community.

對於口服廣譜抗病毒計劃,包括TNX-4200,tonix pharmaceuticals正在利用其先進的研究實驗室能力,包括位於位於馬里蘭州弗雷德裏克的研發中心(RDC)的生物安全 3 級(BSL-3)實驗室和動物生物安全 3 級(ABSL-3)設施,以及公司內擁有經驗豐富的人員。 RDC 位於馬里蘭州「I-270生物技術走廊」,靠近美國生物防禦研究社區中心。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論